钠-葡萄糖协同转运蛋白-2抑制剂在射血分数保留性心力衰竭中的研究进展  

Research progress of sodium-glucose cotransporter-2 inhibitors in heart failure with preserved ejection fraction

作　　者：马兰虎 蓝庆肃 武锋超 姚亚丽[1,2] MA Lanhu;LAN Qingsu;WU Fengchao;YAO Yali(The First Clinical Medical College of Lanzhou University,Lanzhou,Gansu 730000,P.R.China;Heart Center,the First Hospital of Lanzhou University,Lanzhou,Gansu 730000,P.R.China)

机构地区：[1]兰州大学第一临床医学院,兰州730000 [2]兰州大学第一医院心脏中心,兰州730000

出　　处：《华西医学》2021年第9期1288-1292,共5页West China Medical Journal

基　　金：甘肃省卫生行业科研计划项目(GSWSDY-2015-44)。

摘　　要：钠-葡萄糖协同转运蛋白(sodium-glucose cotransporter,SGLT)-2抑制剂是一种新型的口服降糖药物。其作用不依赖胰岛素,而是通过抑制近曲小管葡萄糖重吸收而使葡萄糖从尿液排出,从而降低血糖。SGLT-2抑制剂不仅有降糖作用,而且在心血管疾病中获益明显,此药具有渗透性利尿、减轻容量负荷、改善心室重塑等优点。SGLT-2抑制剂能改善射血分数保留性心力衰竭(heart failure with preserved ejection fraction,HFpEF)患者的舒张功能,并降低心血管不良事件的发生风险。SGLT-2抑制剂应用于HFpEF患者可以使患者获益。因此,该文将探讨SGLT-2抑制剂在HFpEF中的研究进展。Sodium-glucose cotransporter(SGLT)-2 inhibitors is a new type of oral sugar-lowering drug.Instead of relying on insulin,it lowers blood sugar by inhibiting the reabsorption of near-curvy tube glucose,which is drained from the urine.SGLT-2 inhibitors not only have a sugar-lowering effect,but also benefit significantly in cardiovascular disease,and this drug has the advantages of permeable diuretic,reducing capacity load,and improving ventricular remodeling.SGLT-2 inhibitors can improve the diastolic function of patients with heart failure with preserved ejection fraction(HFpEF)and reduce the risk of adverse cardiovascular events.SGLT-2 inhibitors can benefit patients with HFpEF.Therefore,this article will discuss the progress of SGLT-2 inhibitors in HFpEF.

关 键 词：射血分数保留性心力衰竭 钠-葡萄糖协同转运蛋白-2抑制剂 治疗 

分 类 号：R541.6[医药卫生—心血管疾病]